Failure to change provisions of the recently agreed US-Mexico- Canada Free Trade Agreement (USMCA) will “exacerbate the lagging biosimilar market in the US”, slow biosimilar and generic development, and create inconsistencies with US law, according to the US Association for Accessible Medicines (AAM).
AAM slams USMCA trade deal
Failure to change provisions of the recently agreed US-Mexico- Canada Free Trade Agreement (USMCA) will “exacerbate the lagging biosimilar market in the US”, slow biosimilar and generic development, and create inconsistencies with US law, according to the US Association for Accessible Medicines (AAM).
More from Archive
More from Generics Bulletin
• By
Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.
• By
With the Global Generics & Biosimilars Awards 2025 taking place in Frankfurt this October, we bring you five key pieces of guidance to help ensure that your entries stand out from the competition.
• By
Denosumab competition is heating up in Europe, with four more companies this month gaining EMA endorsements for their Prolia and Xgeva biosimilar rivals.